## Thrombolysis For DVT Ups Risk of Death

BY MITCHEL L. ZOLER
Philadelphia Bureau

BALTIMORE — Patients increasingly undergo thrombolysis for deep vein thrombosis, but this treatment significantly boosted the risk of major bleeding and death, according to representative data collected in 1998-2003 from across the United States.

On the basis of these findings, thrombolysis should not be used as an adjunctive treatment for deep vein thrombosis (DVT) in patients who are at high risk for a bleeding complication, Dr. Carlos H. Timaran said at the Vascular Annual Meeting.

Thrombolysis has been advocated as an adjunct to anticoagulant treatment for iliofemoral DVT by certain medical societies because of its effectiveness at reducing postthrombotic syndrome. Until now, it has been viewed as safe, said Dr. Timaran, chief of endovascular surgery at the Dallas Veterans Affairs Medical Center.

High-risk patients who should not get thrombolytic treatment for DVT include those with a history of peptic ulcer disease, stroke, intracranial hemorrhage, or brain surgery. These patients are especially vulnerable to developing a new gastric or intracranial bleed following thrombolytic therapy, he said in an interview.

Dr. Timaran and his associates used data collected in the National Inpatient Sample, a representative, 20% sample of patients treated at academic and community hospitals in 35 states sponsored by the Agency for Healthcare Quality and Research. They analyzed data on thrombolysis for DVT in 1998-2003.

In 1998, about 485,000 hospitalized patients in the United States were diagnosed with DVT, which increased to about 800,000 patients by 2003. Overall, in-hospital mortality rates in these patients rose from 1.07% in 1998 to 1.22% in 2003. Among these patients, the percentage of patients treated with thrombolysis jumped from 0.4% in 1998 to 2.1% in 2003, a fivefold increase.


In a multivariate analysis controlling for differences in the incidence of pulmonary embolism and in the prevalence of comorbidities, patients with DVT who were treated with thrombolysis had a 54% increased risk of developing a major bleed and a 4.9-fold increased risk of having an intracranial hemorrhage, compared with those who weren't treated with thrombolysis. Thrombolytic therapy also boosted the risk of inhospital death by 75%, compared with DVT patients who didn't undergo thrombolysis.

During the period studied, the in-hospital mortality rate of DVT patients who weren't treated with thrombolysis and had no major bleeding was 1.1%, but in those who received thrombolysis and had major bleeding the mortality rate was 8.2%, about sevenfold higher. "The increased risk of death with thrombolysis is primarily associated with an increased risk of major bleeding," he said in an interview.

Drugs commonly used for DVT thrombolysis are tissue plasminogen activator, urokinase, tenecteplase, and reteplase.

We want you to know

Personal Health Record



©2007 Aetna Inc. The Aetna Personal Health Record should not be used as the sole source of information about the member's health conditions or medical treatment. 2007/09

## You and your patients can **make history.**<sup>M</sup>

Aetna is at the forefront of using new technology to help you provide better care. The Personal Health Record is one example. This private, secure online tool gives your patients the option to share their personalized health histories with you, so you'll have more complete, accurate information all in one place. A fuller knowledge of your patients' overall health, such as medical conditions they may have, and medications other doctors may have prescribed, can help inform your diagnoses and treatment recommendations. To find out more, visit aetna.com/provider.

We want you to know®



Health
Dental
Pharmacy
Behavioral Health
Disability
Life